Clinical Trial Update: A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese Participants [Phase 3]

View source ↗

Summary

Phase 3 trial of icatibant for acute attacks of hereditary angioedema in Japanese participants completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• ICATIBANT (icatibant)

Snippet

Sponsor: Shire | Conditions: Hereditary Angioedema (HAE) | Phase 3 | Status: COMPLETED | Results posted: 2019-08-08